FDA advisory committee to meet April 6 on COVID vaccine boosters


A Food and Drug Administration advisory committee is scheduled to meet April 6 to discuss whether there is a need to authorize or approve COVID-19 booster doses in the future. The Vaccines and Related Biological Products Advisory Committee will also talk about creating a process for selecting SARS-CoV-2 virus strains to be included in future doses of the vaccines. (The same committee meets in the spring each year to select the flu strains that are used to make the flu vaccines for the following fall and winter season.) “Now is the time to discuss the need for future boosters as we aim to move forward safely, with COVID-19 becoming a virus like others such as influenza that we prepare for, protect against, and treat,” Dr. Peter Marks, the director of the FDA’s Center for Biologics Evaluation and Research, said in a news release. The FDA said the committee will not be taking a vote and will not discuss specific product applications. Moderna Inc. MRNA, -1.98% as well as BioNTech SE BNTX, -2.49% and Pfizer Inc. PFE, -0.59% have separately asked the regulator to allow fourth doses of their COVID-19 shots.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleBoeing is Dow’s biggest loser as shares slide after reported crash of Boeing 737 jet operated by Chinese airline
Next articleNext Avenue: Why it’s ok to do nothing in retirement—and other times, too


Please enter your comment!
Please enter your name here